ODI Pharma

Adoption of the income statement and balance sheet

The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet.

Allocation of the company's profit or loss

The AGM resolved to dispose of the company's results according to the adopted balance sheet, in accordance with the Board's proposal in the annual report with no dividend to be paid for the financial year 2022/2023. 

Discharge of liability for board members and CEO

The AGM resolved to discharge the members of the board of directors and the managing director from liability for the financial year of 2022/2023.

Determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors

The AGM resolved that the board of directors consist of four (4) ordinary board members and no deputy board member and that one auditor is determined, and no deputy auditors.

Determination of fees for members of the board of directors and auditors

The AGM resolved that the board remuneration should amount to 100,000 SEK for the Chairman of the Board Volker Wiederrich, and 100,000 SEK each for board members Derek Simmross and Karina Kilinski. Additionally, it was resolved that board renumeration should amount to 75,500 SEK for board member Gösta Lidén.

The AGM resolved that the auditors' fees should be paid according to approval invoice in accordance with customary charging standards.

Election of the board of directors and accounting firm or auditor

The AGM resolved that Derek Simmross, Karina Kilinski, Gösta Lidén and Volker Wiederrich be re-elected as ordinary board members. As Chairman of the Board, Volker Wiederrich was re-elected.

The AGM resolved that the company's audit firm Öhrlings PricewaterhouseCoopers AB be re-elected as the company auditor until the end of the Annual General Meeting that is held next financial year.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com 

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.